Jessica C Huston

Jessica C Huston, Pharm.D.

Clinical Assistant Professor

Department: Jacksonville Campus
Business Phone: (904) 244-9590
Business Email: jessicahuston@cop.ufl.edu

About Jessica C Huston

Dr. Jessica Huston is a Clinical Assistant Professor with the University of Florida College of Pharmacy at the Jacksonville Campus. She received her Bachelor’s degree in Biology from the University of Florida and her Doctor of Pharmacy at Virginia Commonwealth University before completing a Post-Doctoral Fellowship in Clinical Research and Pharmaceutical Industry at the East Coast Institute for Research. Dr. Huston joined the University of Florida College of Pharmacy as an Adjunct Clinical Lecturer in 2019 and lectured for the Physician Assistant Program at Nova Southeastern University. Dr. Huston’s research interests include diabetes and heart failure, where she has served as a Sub-Investigator on many clinical studies.

Additional Positions:
Clinical Research Pharmacist
2021 – Current · UF Health Jacksonville

Accomplishments

Teaching Service Award
2021 · UF College of Pharmacy
Excellence in the Promotion of Pharmacy
2018 · Virginia Commonwealth University School of Pharmacy

Teaching Profile

Courses Taught
2020-2023
PHA5165L Prof Skills Lab V
2020-2024
PHA5103 Prin Pt Centered Care
2021-2024
PHA5166L Prof Skills Lab Vi
2021-2024
PHA5164L Prof Skills Lab Iv
2021-2023
PHA5163L Prac Skills Lab III

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-0860-2108

Publications

2023
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
American Journal of Cardiovascular Drugs. 23(4):393-406 [DOI] 10.1007/s40256-023-00583-8. [PMID] 37188993.
2023
A Review of NCX470: A Novel Nitric Oxide-Donating Prostaglandin Analog for Treatment of Glaucoma and Ocular Hypertension
Drugs of the Future. 48(1):1-7
2023
Brincidofovir: A Novel Agent for the Treatment of Smallpox
Annals of Pharmacotherapy. 57(10):1198-1206 [DOI] 10.1177/10600280231151751.
2023
Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia
American Journal of Cardiovascular Drugs. [DOI] 10.1007/s40256-023-00589-2.
2023
Implementation of a series of advanced pharmacy practice experience (APPE) preparatory topics into a skills lab curriculum.
Currents in pharmacy teaching & learning. 15(2):218-223 [DOI] 10.1016/j.cptl.2023.02.029. [PMID] 36898894.
2022
Danuglipron. Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity
Drugs of the Future. 47(6) [DOI] 10.1358/dof.2022.47.6.3373535.
2022
HIV Prevention Utilizing Long-acting Injectables
touchREVIEWS in Infectious Diseases. 1(1)
2022
Icosema: Summary of the Emerging Data for Insulin Icodec and the Study Designs for the Novel GLP-1 Receptor Agonist/Basal Insulin Injection
EC Diabetes and Metabolic Research. 6(2):1-4
2022
Imeglimin in Diabetes Type 2
Drugs of Today. 58(9):437-449
2022
Increasing Importance of Clinical Research Opportunities for Pharmacy Students
Global Journal of Pharmacy & Pharmaceutical Sciences. 10(1):1-2 [DOI] 10.19080/GJPPS.2022.09.555778.
2022
Research and Education Poster Abstracts Presented at the 123rd Annual Meeting of the American Association of Colleges of Pharmacy, July 23-27, 2022; Implementing a Series of Advanced Pharmacy Practice Experience Preparatory Topics into a Skills Lab Curriculum
American Journal of Pharmaceutical Education. 86(5) [DOI] 10.5688/ajpe9171.
2021
A Critical Review of the Efficacy and Safety of Inclisiran.
American journal of cardiovascular drugs : drugs, devices, and other interventions. [DOI] 10.1007/s40256-021-00477-7. [PMID] 33954930.
2021
A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Minimal Arterial Access Lower-Extremity Intervention Via Peripheral Orbital Atherectomy
Vascular Disease Management . 18(6):E89-E94
2021
A Retrospective Cohort Study to Evaluate the Efficacy, Safety, and Cost of MALEI Via Transradial vs Transfemoral Peripheral Revascularizations.
Vascular Disease Management . 18(10):E178-E183
2021
A Review on the Efficacy and Safety of Oral Semaglutide.
Drugs in R&D. [DOI] 10.1007/s40268-021-00341-8. [PMID] 33772451.
2021
Abelacimab. Anti-factor XI/XIa monoclonal antibody, Treatment of atrial fibrillation, Treatment of thrombotic disorders
Drugs of the Future. 46(12) [DOI] 10.1358/dof.2021.46.12.3349024.
2021
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
American Journal of Cardiovascular Drugs. [DOI] 10.1007/s40256-021-00499-1.
2021
Long-Acting Antiretroviral Therapies for HIV Treatment and Prevention
Contagion. 6(3):14-15
2021
MenQuadfi (MenACWY-TT): A New Vaccine for Meningococcal Serogroups ACWY
Annals of Pharmacotherapy. [DOI] 10.1177/10600280211039873.
2020
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 20(6):535-548 [DOI] 10.1007/s40256-020-00399-w. [PMID] 32166726.
2020
A Virtual Community Pharmacy Advanced Pharmacy Practice Experience (APPE) in Response to COVID-19
Journal of Curriculum and Teaching. 9(4):89-94
2020
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention.
American journal of cardiovascular drugs : drugs, devices, and other interventions. 20(5):419-429 [DOI] 10.1007/s40256-020-00397-y. [PMID] 32043244.
2020
Tirzepatide: Summary of the Emerging Data on the Novel GLP-1/GIP Dual Agonist
EC Nutrition. 4(6):12-14
2019
A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data.
Diabetes, metabolic syndrome and obesity : targets and therapy. 12:1897-1911 [DOI] 10.2147/DMSO.S167375. [PMID] 31571964.
2019
Efpeglenatide. Glucagon-like peptide 1 (GLP-1) receptor agonist, Treatment for type 2 diabetes
Drugs of the Future. 44(6) [DOI] 10.1358/dof.2019.44.6.2927591.
2019
Implementation of an interviewing skills workshop for pharmacy students.
Currents in pharmacy teaching & learning. 11(3):277-286 [DOI] 10.1016/j.cptl.2018.12.013.
2019
Praliciguat. Soluble guanylate cyclase activator, Treatment of heart failure with preserved ejection fraction, Treatment of diabetic nephropathy
Drugs of the Future. 44(4) [DOI] 10.1358/dof.2019.44.4.2927592.

Education

PharmD
2014-2018 · VCU/MCV School of Pharmacy
BS Biology
2010-2014 · University of Florida

Contact Details

Phones:
Business:
(904) 244-9590
Emails:
Addresses:
Business Mailing:
508 8th Street W
JACKSONVILLE FL 32209